

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **VOLUNTARY ANNOUNCEMENT**

### **LICENSE AND COLLABORATION AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF QX027N WITH WINDWARD BIO GROUP AG AFFILIATE**

This announcement is made by Qyuns Therapeutics Co., Ltd. (the “**Company**”) on a voluntary basis to inform its shareholders and potential investors of an update on the business developments of the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce that on December 19, 2025, the Company and LE2025 Therapeutics AG (“**LE2025**”), an affiliate of Windward Bio Group AG (“**Windward Bio**”), have entered into a license and collaboration agreement (the “**Agreement**”).

The Agreement grants LE2025 an exclusive right to develop and commercialize QX027N globally, except from mainland China, Taiwan, the Special Administrative Region of Hong Kong and the Special Administrative Region of Macau (the “**Licensed Territory**”). In return, the Company or its designated affiliate(s) (collectively, the “**Group**”) will be entitled to receive a total of up to USD\$700 million payments, including an upfront payment, an equity interest of Windward Bio, development and commercial milestone payments, plus tiered royalties on net sales of QX027N in the Licensed Territory.

#### **ABOUT QX027N**

QX027N is a long-acting anti-TSLPxIL-13 bispecific antibody independently developed by the Company. As mentioned in the voluntary announcement dated November 13, 2025, QX027N has obtained clinical trial approvals from the Center for Drug Evaluation of the National Medical Products Administration (Acceptance Nos.: CXSL2500757, CXSL2500758), intended for the treatment of asthma and atopic dermatitis. On December 12, 2025, the Company successfully initiated the Phase I clinical trial for QX027N by enrolling the first subject in China.

## ABOUT WINDWARD BIO GROUP AG

Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. Its lead program is WIN378, a potential best-in-disease, long-acting anti-TSLP monoclonal antibody currently in Phase II trials for asthma. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific, which has potential broad therapeutic application across immunological diseases. The company is building a pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Qyuns Therapeutics Co., Ltd.**  
**Mr. Qiu Jiwan**  
*Chairman of the Board and Executive Director*

Hong Kong, December 22, 2025

*As at the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.*